Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group

• Published in: British journal of cancer Vol. 100; no. 4; pp. 601 - 607
• Main Authors: Ray-Coquard, I, Weber, B, Cretin, J, Haddad-Guichard, Z, Lévy, E, Hardy-Bessard, A C, Gouttebel, M C, Geay, J-F, Aleba, A, Orfeuvre, H, Agostini, C, Provencal, J, Ferrero, J M, Fric, D, Dohollou, N, Paraiso, D, Salvat, J, Pujade-Lauraine, É
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24-02-2009; Nature Publishing Group
• Subjects: Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Bridged-Ring Compounds - administration & dosage; Cancer Research; Clinical Study; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Dose-Response Relationship, Drug; Drug Resistance; Drug Resistance, Neoplasm; Epidemiology; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Molecular Medicine; Oncology; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Ovarian Neoplasms - drug therapy; Platinum - administration & dosage; Taxoids - administration & dosage; Tumors; toxicity; oxaliplatin; gemcitabine; platinum-resistant; ovarian cancer; combination chemotherapy; Antineoplastic agent; Drug combination; Gemcitabine; Toxicity; Ovary cancer; Malignant tumor; Female genital diseases; Resistance; Ovarian diseases; Alkylating agent; Cancerology; Oxaliplatin; Antimetabolic; Taxane derivatives; Phase II trial; Pyrimidine derivatives; Combined treatment; Fluorine Organic compounds; Pyrimidine nucleoside; Cancer; Platinum II Complexes
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6604878

Advanced ovarian carcinoma in early progression (<6 months) (AOCEP) is considered resistant to most cytotoxic drugs. Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity in relapsed ovarian cancer. Their combination was tested in patients with AOCEP in phase II study. Fifty patients pre-treated with platinum–taxane received q3w administration of OXA (100 mg m
–2
, d1) and GE (1000 mg m
–2
, d1, d8, 100-min infusion). Patient characteristics were a : median age 64 years (range 46–79),and 1 (84%) or 2 (16%) earlier lines of treatment. Haematological toxicity included grade 3–4 neutropaenia (33%), anaemia (8%), and thrombocytopaenia (19%). Febrile neutropaenia occurred in 3%. Non-haematological toxicity included grade 2–3 nausea or vomiting (34%), grade 3 fatigue (25%),and grade 2 alopecia (24%). Eighteen (37%) patients experienced response. Median progression-free (PF) and overall survivals (OS) were 4.6 and 11.4 months, respectively. The OXA–GE combination has high activity and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA–GE with single-agent treatment is warranted.